{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Targeted+agent&page=42",
    "query": {
      "intervention": "Targeted agent",
      "page": 42
    },
    "page_size": 10
  },
  "pagination": {
    "page": 42,
    "page_size": 10,
    "total_count": 1322,
    "total_pages": 133,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Targeted+agent&page=43&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Targeted+agent&page=41&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-05T06:23:56.501Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00454649",
      "title": "Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "Axitinib + Paclitaxel + Carboplatin (Cohort 1)",
          "type": "DRUG"
        },
        {
          "name": "Axitinib + Paclitaxel + Carboplatin (Cohort 2)",
          "type": "DRUG"
        },
        {
          "name": "Axitinib + Paclitaxel + Carboplatin (Cohort 3)",
          "type": "DRUG"
        },
        {
          "name": "Axitinib + Paclitaxel (Cohort 4)",
          "type": "DRUG"
        },
        {
          "name": "Axitinib + Docetaxel + Carboplatin (Cohort 4a)",
          "type": "DRUG"
        },
        {
          "name": "Axitinib + Docetaxel (Cohort 5)",
          "type": "DRUG"
        },
        {
          "name": "Axitinib + Capecitabine (Cohort 6)",
          "type": "DRUG"
        },
        {
          "name": "Axitinib + Capecitabine (Cohort 7)",
          "type": "DRUG"
        },
        {
          "name": "Axitinib + Gemcitabine + Cisplatin (Cohort 8)",
          "type": "DRUG"
        },
        {
          "name": "Axitinib + Pemetrexed + Cisplatin (Cohort 9)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 102,
      "start_date": "2005-12",
      "completion_date": "2011-04",
      "has_results": true,
      "last_update_posted_date": "2012-04-04",
      "last_synced_at": "2026-11-05T06:23:56.501Z",
      "location_count": 10,
      "location_summary": "Augusta, Georgia • Harvey, Illinois • Tinley Park, Illinois + 5 more",
      "locations": [
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Harvey",
          "state": "Illinois"
        },
        {
          "city": "Harvey",
          "state": "Illinois"
        },
        {
          "city": "Tinley Park",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00454649"
    },
    {
      "nct_id": "NCT00881920",
      "title": "Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma",
        "Myeloma",
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "Kappa CD28 T cells",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2009-07",
      "completion_date": "2035-07",
      "has_results": false,
      "last_update_posted_date": "2026-10-05",
      "last_synced_at": "2026-11-05T06:23:56.501Z",
      "location_count": 2,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00881920"
    },
    {
      "nct_id": "NCT02293096",
      "title": "Pharmacogenetic Prediction of Metoprolol Effectiveness",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hypertension"
      ],
      "interventions": [
        {
          "name": "metoprolol succinate",
          "type": "DRUG"
        },
        {
          "name": "Genotyping",
          "type": "GENETIC"
        },
        {
          "name": "CYP2D6 Phenotyping",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "GENETIC",
        "PROCEDURE"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "30 Years to 80 Years"
      },
      "enrollment_count": 462,
      "start_date": "2014-09",
      "completion_date": "2017-08-23",
      "has_results": true,
      "last_update_posted_date": "2021-09-16",
      "last_synced_at": "2026-11-05T06:23:56.501Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02293096"
    },
    {
      "nct_id": "NCT06447662",
      "title": "A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Carcinoma, Pancreatic Ductal",
        "Colorectal Neoplasms",
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "interventions": [
        {
          "name": "PF-07934040",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Nab-paclitaxel",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Cetuximab",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Fluorouracil",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Oxaliplatin",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Leucovorin",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Bevacizumab",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Pembrolizumab",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "pemetrexed",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Cisplatin",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Paclitaxel",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Carboplatin",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Sasanlimab",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 64,
      "start_date": "2024-06-27",
      "completion_date": "2026-10-09",
      "has_results": false,
      "last_update_posted_date": "2026-10-13",
      "last_synced_at": "2026-11-05T06:23:56.501Z",
      "location_count": 26,
      "location_summary": "Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 14 more",
      "locations": [
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06447662"
    },
    {
      "nct_id": "NCT03173560",
      "title": "Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "lenvatinib",
          "type": "DRUG"
        },
        {
          "name": "everolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 343,
      "start_date": "2017-08-17",
      "completion_date": "2024-06-20",
      "has_results": true,
      "last_update_posted_date": "2025-04-01",
      "last_synced_at": "2026-11-05T06:23:56.501Z",
      "location_count": 8,
      "location_summary": "Duarte, California • Whittier, California • Miami, Florida + 5 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        },
        {
          "city": "Tulsa",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03173560"
    },
    {
      "nct_id": "NCT03371082",
      "title": "Gan & Lee Insulin Glargine Target Type (1) Evaluating Research",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 1"
      ],
      "interventions": [
        {
          "name": "Gan & Lee Insulin Glargine Injection",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Lantus®",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Gan and Lee Pharmaceuticals, USA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 576,
      "start_date": "2017-10-31",
      "completion_date": "2019-08-19",
      "has_results": true,
      "last_update_posted_date": "2024-05-14",
      "last_synced_at": "2026-11-05T06:23:56.501Z",
      "location_count": 50,
      "location_summary": "Birmingham, Alabama • Fresno, California • Newport Beach, California + 41 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Northridge",
          "state": "California"
        },
        {
          "city": "Tarzana",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03371082"
    },
    {
      "nct_id": "NCT05799157",
      "title": "Safety and Efficacy of VDMN-21 Patch in Subjects With Common Warts",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Verruca Vulgaris",
        "Warts",
        "Common Wart"
      ],
      "interventions": [
        {
          "name": "VDMN-21 Patch Low Dose",
          "type": "DRUG"
        },
        {
          "name": "VDMN-21 Patch High Dose",
          "type": "DRUG"
        },
        {
          "name": "Vehicle Patch",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Veradermics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "9 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "9 Years to 65 Years"
      },
      "enrollment_count": 153,
      "start_date": "2023-02-28",
      "completion_date": "2025-02-25",
      "has_results": false,
      "last_update_posted_date": "2025-05-08",
      "last_synced_at": "2026-11-05T06:23:56.501Z",
      "location_count": 16,
      "location_summary": "Fort Smith, Arkansas • San Diego, California • Plainfield, Indiana + 13 more",
      "locations": [
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Plainfield",
          "state": "Indiana"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Baton Rouge",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05799157"
    },
    {
      "nct_id": "NCT01149434",
      "title": "Study of JI-101 in Patients With Advanced Low Grade Endocrine Tumors, Ovarian Cancers or K-RAS Mutant Colon Cancers",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Cancer",
        "Neuroendocrine",
        "Ovarian Cancer",
        "Colon Cancer"
      ],
      "interventions": [
        {
          "name": "JI-101",
          "type": "DRUG"
        },
        {
          "name": "Everolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2010-09",
      "completion_date": "2012-08",
      "has_results": true,
      "last_update_posted_date": "2014-10-06",
      "last_synced_at": "2026-11-05T06:23:56.501Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01149434"
    },
    {
      "nct_id": "NCT02698293",
      "title": "PDT Plus Vitamin D3 for Anal Dysplasia",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Anal Dysplasia",
        "Carcinoma in Situ"
      ],
      "interventions": [
        {
          "name": "Gliolan",
          "type": "DRUG"
        },
        {
          "name": "Vitamin D3 cholecalciferol)",
          "type": "DRUG"
        },
        {
          "name": "Photodynamic Therpay",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Abramson Cancer Center at Penn Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2019-12-01",
      "completion_date": "2022-08-03",
      "has_results": false,
      "last_update_posted_date": "2026-08-04",
      "last_synced_at": "2026-11-05T06:23:56.501Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02698293"
    },
    {
      "nct_id": "NCT06439693",
      "title": "The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer Female",
        "Breast Cancer",
        "Breast Cancer Metastatic",
        "Estrogen Receptor-positive Breast Cancer",
        "HER2-positive Breast Cancer",
        "Stage IV Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Nab-Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Phesgo",
          "type": "DRUG"
        },
        {
          "name": "T-DM1",
          "type": "DRUG"
        },
        {
          "name": "Pertuzumab",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab Deruxtecan",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab Subcutaneous Subcutaneous",
          "type": "DRUG"
        },
        {
          "name": "Tucatinib",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 72,
      "start_date": "2024-08-08",
      "completion_date": "2033-03-30",
      "has_results": false,
      "last_update_posted_date": "2026-08-06",
      "last_synced_at": "2026-11-05T06:23:56.501Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06439693"
    }
  ]
}